Composition for improving efficiency of drug delivery

• US 8,391,959 B2
• Filed: 09/29/2005
• Issued: 03/05/2013
• Est. Priority Date: 09/29/2004
• Status: Expired due to Fees

• Current Assignee: Medical Research Fund of -Tel Aviv Sourasky Medical Center, Tel Hashomer Medical Research Infrastructure And Services Ltd.
• Original Assignee: Medical Research Fund of -Tel Aviv Sourasky Medical Center, Tel Hashomer Medical Research Infrastructure And Services Ltd.
• Inventors: Mardor, Yael, Ram, Zvi
• Primary Examiner(s): Goddard, Laura B
• Application Number:
  US11/664,126
• Publication Number:
  US 20090208422A1
• Time in Patent Office: 2,714 Days
• Field of Search: None
• US Class Current: 600/433
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 47/44 Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14
• CPC Class Codes: A61K 49/1824 coated or functionalised nanoparticles liposomes A61K49/1812; nanoemulsions A61K49/1806; micelles A61K49/1809
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00

Abstract

Method and composition suitable for administering by direct convective interstitial infusion are disclosed. The method comprises: placing at least one direct convective interstitial infusion catheter in contact with the tissue, and pressuring the composition through the catheter. The composition is in a liquefied form having a viscosity above a predetermined value. The predetermined value is selected so as to improve infusion of the compositions into interstitial volumes of the tissue, while minimizing backflow of the compositions along an outer wall of the catheter or leakage into low resistance paths. It is demonstrated that high viscosity results in higher treatment efficiency.

Claims

1. A method of administering a pharmaceutical agent to a tissue by direct convective interstitial infusion, the method comprising:

placing at least one direct convective interstitial infusion catheter in contact with the tissue;

pressuring said pharmaceutical agent in a liquefied form having a viscosity being X times larger than a viscosity of saline through said at least one direct convective interstitial infusion catheter, wherein said pressuring is characterized by a flow rate selected to induce interstitial convection of said liquefied form, wherein said X is from about 1.04 to about 1.7.

2. The method of claim 1, wherein said pressuring said pharmaceutical agent is characterized by a flow rate larger than 4 microliters per minute, and is executed while substantially minimizing backflow of said pharmaceutical agent along an outer wall of said at least one direct convective interstitial infusion catheter.

3. The method of claim 1, wherein the tissue is a tumor.

4. The method of claim 1, wherein the tissue is a brain tumor.

5. The method of claim 1, wherein the tissue is a brain pathology.

6. The method of claim 1, wherein the tissue is a spine pathology.

7. The method of claim 1, wherein the tissue is a prostate pathology.

8. The method of claim 1, wherein the tissue is a pancreas pathology.

9. The method of claim 1, wherein the tissue is a kidney pathology.

10. The method of claim 1, wherein the tissue is a liver pathology.

11. The method of claim 1, wherein said pharmaceutical agent comprises a therapeutic agent.

12. The method of claim 11, wherein said therapeutic agent has a molecular weight of at least 200 kDa.

13. The method of claim 1, wherein said pharmaceutical agent in said liquefied form comprises a nanoparticle.

14. The method of claim 1, wherein said pharmaceutical agent in said liquefied form comprises a liposome.

15. The method of claim 1, wherein said pharmaceutical agent in said liquefied form comprises stem cells.

16. The method of claim 1, wherein said pharmaceutical agent in said liquefied form comprises macrophages.

17. The method of claim 1, wherein said pharmaceutical agent comprises a diagnostic agent.

18. The method of claim 17, wherein said diagnostic agent comprises an MRI contrast agent.

19. The method of claim 18, wherein said MRI contrast agent has a T1 shortening effect.

20. The method of claim 1, wherein said viscosity value is equal to a viscosity of human serum albumin at a concentration of about 0.2%.

21. The method of claim 1, further comprising imaging a region containing the tissue by MRI thereby providing at least one image of said region.

22. The method of claim 21, further comprising using said at least one image for monitoring the convection of said pharmaceutical composition within the tissue.

23. The method of claim 21, further comprising dissolving or dispersing an MRI contrast agent in said pharmaceutical composition.

41. The method of claim 19, wherein said MRI contrast agent comprises a diethylenetriamine pentaacetic acid (DTPA).

42. The method of claim 19, wherein said paramagnetic metal comprises Gadolinium (Gd).

43. The method of claim 19, wherein said MRI contrast agent comprises Gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA).

24. A method of administering a pharmaceutical composition to a tissue by direct convective interstitial infusion, the pharmaceutical composition being in a liquid form, the method comprising:

placing at least one direct convective interstitial infusion catheter in contact with the tissue;

increasing a viscosity of the pharmaceutical composition to a viscosity value being X times larger than a viscosity of saline, wherein said X is from about 1.04 to about 1.7; and

pressuring the pharmaceutical composition through said at least one direct convective interstitial infusion catheter, wherein said pressuring is characterized by a flow rate selected to induce interstitial convection of said liquid form.

25. The method of claim 24, wherein said predetermined value is selected so as to allow pressuring of the pharmaceutical composition at a flow rate larger than 4 microliters per minute, while substantially minimizing backflow of said pharmaceutical agent along an outer wall of said at least one direct convective interstitial infusion catheter.

26. A direct convective interstitial infusion method, comprising:

providing a pharmaceutical composition which comprises a therapeutic agent and an MRI contrast agent, the pharmaceutical composition being in liquid form and having a viscosity being X times larger than a viscosity of saline, wherein said X is from about 1.04 to about 1.7;

pressuring said pharmaceutical composition through at least one direct convective interstitial infusion catheter into an interstitial volume of a tissue, wherein said pressuring is characterized by a flow rate selected to induce interstitial convection of said liquid form;

imaging a region containing the tissue by MRI thereby providing at least one image of said region; and

using said at least one image for monitoring the convection of said therapeutic agent within the tissue, wherein said monitoring the convection comprises detecting backflow of said pharmaceutical composition along said at least one direct convective interstitial infusion catheter.

27. The method of claim 26, wherein said MRI contrast agent is selected so as to allow convection of said MRI contrast agent together with said therapeutic agent, while prolonging a time in which said MRI contrast agent remains in the tissue.

28. The method of claim 26, wherein said monitoring the convection comprises comparing the images with baseline images.

29. The method of claim 26, wherein said monitoring the convection comprises correlating intensity level of the images with level of presence of said therapeutic agent.

30. The method of claim 26, wherein said monitoring the convection comprises correlating intensity level of the images with a concentration of said therapeutic agent.

31. The method of claim 26, wherein said monitoring the convection comprises calculating distribution volume of said pharmaceutical composition.

32. The method of claim 26, wherein said monitoring the convection comprises calculating expansion rate of said pharmaceutical composition.

33. The method of claim 26, wherein said monitoring the convection comprises determining a direction of expansion of said pharmaceutical composition.

34. The method of claim 26, wherein said monitoring the convection comprises detection leakage of said pharmaceutical composition into low resistance paths.

35. The method of claim 26, further comprising providing diffusion-weighted or T2-weighted magnetic resonance images of said tissue, and using said diffusion-weighted or T2-weighted magnetic resonance images for determining the response of the tissue to the direct convective interstitial infusion.

36. The method of claim 35, wherein the response of the tissue comprises a cytotoxic response.

37. The method of claim 35, wherein the response of the tissue comprises a necrotic response.

38. The method of claim 35, wherein the response of the tissue comprises an inflammatory response.

39. The method of claim 35, wherein said determining the response of the tissue comprises calculating apparent diffusion coefficient (ADC) of the tissue and correlating said ADC with the response of the tissue.

40. The method of claim 39, wherein said determining the response of the tissue comprises generating an ADC map of the tissue and of neighboring tissues.

44. A method of administering a pharmaceutical agent to a tissue by direct convective interstitial infusion, the method comprising:

placing at least one direct convective interstitial infusion catheter in contact with the tissue;

pressuring said pharmaceutical agent in a liquefied form having a viscosity which is equal to a viscosity of human serum albumin at a concentration of about 0.2% through said at least one direct convective interstitial infusion catheter, wherein said pressuring is characterized by a flow rate selected to induce interstitial convection of said liquefied form.